Vanderbilt University Medical Center: Study to Assess Allergic Reactions to COVID-19 Vaccines
March 19, 2021
March 19, 2021
NASHVILLE, Tennessee, March 19 (TNSRes) -- Vanderbilt University Medical Center issued the following news:
Vanderbilt University Medical Center is recruiting volunteers for a randomized controlled phase 2 clinical trial to help determine the prevalence of systemic allergic reactions (SARS) to the two-dose COVID-19 mRNA vaccines made by Pfizer-BioNTech and Moderna.
True allergies associated with these vaccines appear to be quite rare, in the range of only three to four c . . .
Vanderbilt University Medical Center is recruiting volunteers for a randomized controlled phase 2 clinical trial to help determine the prevalence of systemic allergic reactions (SARS) to the two-dose COVID-19 mRNA vaccines made by Pfizer-BioNTech and Moderna.
True allergies associated with these vaccines appear to be quite rare, in the range of only three to four c . . .